Who are Gemigliptin/Glimepiride combination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Teneligliptin + Sulfonylurea, Alogliptin and glyburide.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemigliptin-glimepiride-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gemigliptin/Glimepiride combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemigliptin/Glimepiride combination (Gemigliptin/Glimepiride combination) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor + sulfonylurea combination. Area: Diabetes.

phase 3 DPP-4 inhibitor + sulfonylurea combination DPP-4 (dipeptidyl peptidase-4) and sulfonylurea receptor (SUR1) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Gemigliptin/Glimepiride combination (Gemigliptin/Glimepiride combination) — LG Life Sciences. Gemigliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and insulin secretion, while glimepiride stimulates pancreatic beta cells to release insulin directly.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gemigliptin/Glimepiride combination TARGET	Gemigliptin/Glimepiride combination	LG Life Sciences	phase 3	DPP-4 inhibitor + sulfonylurea combination	DPP-4 (dipeptidyl peptidase-4) and sulfonylurea receptor (SUR1)
Teneligliptin + Sulfonylurea	Teneligliptin + Sulfonylurea	Tanabe Pharma Corporation	phase 3	DPP-4 inhibitor + Sulfonylurea combination	DPP-4 enzyme; ATP-sensitive potassium channels on pancreatic beta cells
Alogliptin and glyburide	Alogliptin and glyburide	Takeda	phase 3	DPP-4 inhibitor + sulfonylurea combination	DPP-4 (dipeptidyl peptidase-4) and sulfonylurea receptor (SUR1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor + sulfonylurea combination class)

LG Life Sciences · 1 drug in this class
Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemigliptin/Glimepiride combination — Competitive Intelligence Brief. https://druglandscape.com/ci/gemigliptin-glimepiride-combination. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing